Drugs / ACT-777991
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04798209 | Jan 2021 → Jan 2022 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07667569 | Jun 2026 → Jun 2027 expected | vitiligo | Idorsia Pharmaceuticals Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-777991 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04798209 ↗ |
| Route | Oral | “ACT-777991 administered as hard capsules for oral use” NCT04798209 ↗ |